Positioning Early Phase CNS Trials For Regulatory And Investor Success: Strategic Implications Of The Single Phase 3 Approval Paradigm

By Peter Schmidt, PhD, and Sheldon Preskorn, MD

The FDA’s 2026 shift toward making a single pivotal Phase 3 trial the default pathway for drug approval is poised to reshape how CNS therapies are developed, funded, and valued. Rather than relying on statistical redundancy across multiple late-stage studies, success increasingly depends on generating compelling mechanistic and biological evidence during Phase 1 and Phase 2 development. For sponsors, this creates a new imperative: design early-phase trials that do more than establish safety and dosing. Biomarker strategies, pharmacokinetic and pharmacodynamic characterization, patient enrichment approaches, and early FDA engagement can help build the confirmatory evidence needed to support a single-trial approval strategy.

Explore case examples that demonstrate how biomarker-informed development programs can strengthen regulatory confidence and improve strategic positioning. Sponsors, CROs, and investors who adapt to this evolving framework may gain a significant competitive edge in an increasingly evidence-driven development landscape.